FindTrial
Sign In

Cancer risk in type 2 diabetes patients treated with sulfonylurea.

Within-class differences in cancer risk for sulfonylurea treatments in patients with type 2 diabetes (ZODIAC-55)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON26303
Enrollment
Unknown
Registered
2017-01-06
Start date
2017-01-30
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes, cancer, kanker.

Interventions

Individual sulfonylurea treatment (gliclazide, glimepiride, tolbutamide, glibenclamide)

Sponsors

Diabetes Centre Isala
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Type 2 diabetes patients treated with sulfonylureas

Exclusion criteria

Exclusion criteria: Type 2 diabtes patientes treated with long-acting or mixed insulin before oral glucose lowering agents and those receiving insulin on top of sulfonylurea at study entry.

Design outcomes

Primary

MeasureTime frame
Within-sulfonylurea-class differences in obesity-related cancer risk (hazard ratio).—

Secondary

MeasureTime frame
Within-sulfonylurea-class differences in all cancer risk and site specific cancer risk of breast, colorectal, bladder, advanced prostate cancer and lung cancer, expressed as hazard ratio.—

Contacts

Public ContactDennis Schrijnders

Dr. Spanjaardweg 11, 2e etage

d.schrijnders@isala.nl0031-38-4247763

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)